Disclosure Of Fair Value Measurement [Text Block]

Xbrane Biopharma - Filing #689992

Concept	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31
Disclosure of fair value measurement [text block]	—	—	—	—	—		—	—	—	—	—	—	—	—	—	—
Disclosure of fair value measurement of assets [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of fair value measurement of assets [abstract]
Disclosure of fair value measurement of assets [line items]
Assets	690 515 SEK	—	—	—	—	—	688 427 SEK	—	—	—	—	—	—	—	—	—
Reconciliation of changes in fair value measurement, assets [abstract]
Disclosure of fair value measurement of liabilities [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of fair value measurement of liabilities [abstract]
Disclosure of fair value measurement of liabilities [line items]
Liabilities	265 626 SEK	—	—	—	—	—	256 686 SEK	—	—	—	—	—	—	—	—	—
Reconciliation of changes in fair value measurement, liabilities [abstract]
Disclosure of fair value measurement of equity [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of fair value measurement of equity [abstract]
Disclosure of fair value measurement of equity [line items]
Equity	424 888 SEK	1 294 227 SEK	885 827 SEK	6 166 SEK	10 322 SEK	—	431 741 SEK	713 313 SEK	1 134 276 SEK	5 165 SEK	5 614 SEK	257 709 SEK	4 977 SEK	524 938 SEK	3 945 SEK	773 724 SEK
Reconciliation of changes in fair value measurement, entity's own equity instruments [abstract]